semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-small Cell Lung Cancer Thoracic Surgery Age > 18 years 2. Peripheral lung tumour that is <2 cm in size on a CT scan 3. Fit to undergo thoracic surgery as assessed by the surgeon  Hypersensitivity or allergy to ICG, sodium iodide or iodine 2. Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pituitary Adenoma •newly diagnosed GH-releasing pituitary adenoma •newly diagnosed Cushing Syndrome  •history of diabetes mellitus and being treated with drugs •being treated with drugs which affect glucose metabolism in the lately 3 months •with other hormones affecting glucose metabolism secreted abnormally by pituitary •serious comorbidity like malignant tumour, severe hepatosis or nephropathy, serious hypertension(blood pressure> 180/110mmhg) •pregnant or breastfeeding women •patients allergic to patches or metal
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Glioblastoma Patients with suspicion of newly diagnosed high-grade glioma who qualify for the standard treatment. Written informed consent  Patients with recurrent high-grade glioma or other brain tumor as a secondary diagnosis are excluded In addition, all patients who have had previous brain surgery or radiotherapy to the brain are also excluded Patients with only a biopsy will be excluded. Patients under the age of 18 years will not be included General for MRI are for participation in this study. The general MRI are: not MRI compatible ferromagnetic material, pregnancy (or presumption thereof) and claustrophobia
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acute Pain Scheduled for unilateral TKA under regional anesthesia ASA Class 1, 2 or 3 Able to give informed consent Able to understand English  Medical condition(s) that prevents use of regional anesthesia (e.g. infection at site of injection, coagulopathy, severe hypovolemia, severe aortic or mitral stenosis, increased intracranial pressure, severe spinal deformity, spinal cord hardware or stimulator implanted) Allergy to morphine Morbid obesity (BMI > 45) Respiratory compromise (difficult airway, severe emphysema or COPD) Obstructive sleep apnea (only if diagnosed in a sleep disorders clinic and CPAP was prescribed) Chronic pain with opioid usage over 100 mg morphine-equivalents po/day History of abuse of opioids or other drugs of abuse Scheduled for bilateral TKA Revision of knee arthroplasty Any medical condition that would affect the patient's ability to metabolize or excrete the study drugs (e.g. chronic kidney failure with patient on dialysis) or other medical condition that in the investigator's opinion would render the patient unsuitable for this research study
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms Pituitary Neoplasms Adult patients over 18 years of age 2. Patients presenting with a pituitary nodule presumed to be resectable on pre-operative assessment 3. Good operative candidate 4. Subject capable of giving informed consent and participating in the process of consent  Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery 2. Patients with a history of anaphylactic reactions to OTL38 3. Patients with a known allergy to Benadryl 4. Previous exposure to OTL38
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Advanced Solid Malignant Tumors Advanced solid malignant tumors that are refractory to standard therapy or for which no standard therapy is available An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1  Previously had or currently has any of the following diseases: Cardiac failure (NYHA Functional Classification ≥ Class III), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary/peripheral artery disease, pulmonary thrombosis, uncontrolled deep vein thrombosis, clinically severe thromboembolic event, or autoimmune disease requiring treatment Previously had or currently has clinically severe pulmonary disease (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, radiation pneumonia) Severe or uncontrolled concomitant disease Clinically active brain metastases or central nervous system tumor requiring steroid or anticonvulsant treatment
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acromegaly Confirmed diagnosis of acromegaly Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months Biochemical control (IGF -1 < 1.3 x ULN and GH < 2.5ng/mL)  Injections of long-acting somatostatin analogs, at a dosing interval > 8 weeks Pituitary radiotherapy within 5 years Pituitary surgery within six months Patients who previously participated in CH-ACM-01 study Any clinically significant uncontrolled concomitant disease Symptomatic cholelithiasis Previous treatment with Pegvisomant, within 12 weeks Dopamine agonists, within 6 weeks Pasireotide, within 12 weeks
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Advanced Solid Malignant Tumors Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available Eastern Cooperative Oncology Group performance status (PS) of 0 or 1  Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment: • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia) Severe or uncontrolled concomitant disease Clinically active brain metastases defined as symptomatic or requiring treatment
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 19.0-90.0,  Prostate Cancer Diagnosis of prostate cancer (by prostate biopsy) Scheduled to undergo a prostatectomy Ability to give his own consent to participate in the study  Serum 25(OH)D level less than 8ng/ml or greater than 50 ng/ml Vitamin D3 supplementation greater than or equal to 1000 IU daily
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hyponatremia Pituitary Adenoma 80 years of age Functioning or non-functioning pituitary adenoma Sodium level 135-145 prior to surgery  Enrolled in a separate pituitary research study Unable to provide his/her own consent Unable to take PO water Renal insufficiency Require maintenance corticosteroids pre-operatively TSH secreting tumor Patients who the treating surgeon deems a poor candidate for the water challenge Prisoners Pregnant women
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 35.0-65.0,  Cavernous Sinus Meningioma Pituitary Adenoma Age between 35 and 65 Patient with meningioma of the cavernous sinus for which radiotherapy is planned or a pituitary adenoma for which radiotherapy is planned French Mother tongue Person affiliated to national insurance Person who give its verbal agreement to participate  Presence of a serious psychiatric disorder (major depression, psychotic disorders, etc.) and central nervous system disease (epilepsy, multiple sclerosis, etc.) Treatment with chemotherapy General intellectual abilities deficient (IQ <80) Extension front of their meningioma Deficient Language Skills
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Adenomas Patients >18 year-old diagnosis of NFPAs confirmed with hormonal and histological analysis patients who underwent surgery in neurosurgery unit of the Reims university hospital between 01/01/1991 and 31/12/2004
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Pituitary Tumor Patients over age 19 Scheduled to undergo transsphenoidal surgery for pituitary tumor ASA class I and II  Left ventricular ejection fraction < 55% Third-degree atrioventricular block Second-degree atrioventricular block (P:QRS ratio of 3:1 or higher) Fever History of myocardial infarction, stroke or cardiac surgery within the previous 1 year Severe neurological disease Use of sedative, opioid or sleep-inducing drugs Allergic history of any study drug Pregnancy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Voice Quality Endoscopic Pituitary Surgery Patients who underwent endoscopic endonasal transsphenoidal skull base surgery  Patients under 18 year Patients cannot following command including loss of conscious Patients cannot speak including patient on tracheostomy tube Patients who has nasal tumor, nasal polyp, sinusitis Patients who has cleft lip cleft palate or submucosal cleft Patients who underwent adenotonsillectomy or palatoplasty in same setting with endoscopic pituitary surgery
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Uveal Melanoma Aged 18 years old or more 2. Patient with hepatic injury of metastatic uveal melanoma eligible for curative surgery (R0). 3. No other distant metastasis (CT thoracic -abdomino -pelvic, bone scan).Measurable metastatic disease (echography, CT and/or MRI, FDG-PET, (fluoro D-glucose integrated with computed tomography)). 4. Patient able to stand a blood collection. 5. Patient explanation given and consent information signed or by legal representative  Patient without social protection / insurance.. 7. Patient with hepatic metastasis unresectable by surgery 8. Patient with extra-hepatic metastasis. 9. Person deprived of liberty or under guardianship 10. Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Developmental Dysplasia of the Hip previous PAO and hip arthroscopy developmental dysplasia of the hip  calve legg perthes disease femoral osteotomy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Adult patients (at least 18 years old) with confirmed acromegaly whose IGF-I levels are persistently but modestly (1.0 ULN < [IGF-1 serum level] < 1.5 ULN) elevated following medical therapy such as SSA, PEGV, cabergoline alone or in combination  Progressive or recent visual field loss or optic chiasmal compression, or pituitary tumors within 2mm from the chiasm. Patients whose visual field loss, optic chiasmal compression or pituitary tumor has been stable for at least a year will be eligible. 2. Cranial nerve palsies or intracranial hypertension requiring tumour decompression surgery 3. Clinically significant hepatic disease and/or elevated liver enzymes (ALT, AST > 3 x ULN) 4. Patients who have received pituitary surgery within one year prior to screening visit 5. Patients who have received radiation therapy within one year prior to screening visit 6. History of hypersensitivity to any components of Pegvisomant 7. Inability to fully comprehend the nature of the study or cooperate with study procedures 8. Pregnant / lactating women and subjects refusing to use adequate contraception to prevent pregnancy during the study. 9. Subjects unwilling or unable to self-administer medication on a daily basis 10. known or suspected alcohol / drug abuse 11. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-84.0,  Antibiotics Pituitary Adenoma Adult patient undergoing endoscopic surgery for resection of pituitary tumors for nonfunctioning adenoma, acromegaly, or prolactinoma Adults >18 and <85 years of age English speaking and able to understand the ASK Nasal-12 and SNOT-22 scales Free of any physical, mental, or medical condition which, in the opinion of the investigator, makes study participation inadvisable  Anaphylaxis/intolerance to the study drugs Cirrhosis, hepatitis Any solid organ transplant or bone marrow transplant. And any patient felt to be immunocompromised by the investigators Renal failure on dialysis Any subject who is unwilling or unable to sign informed consent for the study Pregnancy Incarcerated patients Cushing's disease Rathke's Cleft cyst or pituitary cyst History of chronic sinusitis